Drug Profile
Tazofelone
Alternative Names: LY 213829Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Unknown
- Developer Shire Pharmaceuticals Group
- Class Anti-inflammatories; Irritable bowel syndrome therapies; Phenols; Thiazolidines
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Crohn's disease; Irritable bowel syndrome; Ulcerative colitis
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 06 Jul 2000 Discontinued-II for Irritable bowel syndrome in USA (Rectal)
- 21 Jun 2000 Tazofelone is available for licensing (http://www.shire.com)